Moreover, our study failed to answer whether venetoclax-based regimen could induce a sustainable survival benefit in KIT mut/CBF-neg AML, which needs prospective study with large sample size and long-term follow-up. This evidence concerns the gene CEBPZ and acute myeloid leukemia.